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Staphylococcus aureus is the primary cause of nosocomial infections. It produces potent toxins and causes superficial 
lesions, systemic diseases, and several toxaemic syndromes. In this study, we determined the role of efflux pump in conferring 
resistance to fluoroquinolones in the biofilm of methicillin resistant Staphylococcus aureus (MRSA) and methicillin sensitive 
S. aureus (MSSA) strains. We selected five strains of S. aureus comprising three methicillin sensitive strains, including 
ATCC25923, and two strains of methicillin resistant S. aureus. Thioridazine, chlorpromazine, carbonyl cyanide 3-chloro-
phenylhydrazone and reserpine showed activity against MSSA strains. Whereas, thioridazine and chlorpromazine were active 
against MRSAstrains too. Thioridazine and chlorpromazine showed a significant decrease in biofilm formation of MSSA 
strain 2493, and MRSA strain UC1079 compared to the control strain ATCC25923. Thioridazine showed a similar effect on 
MSSA strain N297214 and MRSA strain N307002. Four to eight-fold increase was found in the expression of efflux pump 
genes with ethidium bromide, ciprofloxacin, and moxifloxacin in these strains. However, a decrease in the expression of norB, 
norC, abcA and mepA was observed in MSSA, and MRSA strains with thioridazine, chlorpromazine and naringenin. This 
study, thus demonstrate that the major facilitator superfamily, multidrug and toxin compound extrusion, and ATP binding 
cassette family of efflux pumps play an essential role in developing antibiotic resistance and biofilm formation. It is the first 
report on existence of efflux pump genes in biofilm beside antibiotic resistance for fluoroquinolones in MRSA and MSSA 
strains, which need further characterization.  
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Staphylococcus aureus is an opportunistic pathogen 
that causes a variety of infections in human, such as 
skin and soft tissue infections, endocarditis, and 
bacteremia. Antibiotic resistance has been one of the 
problems in the treatment of S. aureus infections. 
Efflux of antibiotics mediated by efflux pumps led to 
the emergence of multidrug resistance among 
bacteria1. These efflux pumps remove the toxic 
substances or decrease the intracellular concentration 
of antibiotics in the cytoplasm2. Also, efflux pumps act 
as a defense mechanism that prevents a drug from 
reaching a lethal level inside the cell3. S. aureus 
possesses many potential multidrug resistant (MDR) 
efflux pump encoding genes, of which efflux pumps 
like qacA and qacB, belonging to the major facilitator 
superfamily (MFS), are encoded on plasmids. 
On the other hand, the major MFS pump, norA, 
mdeA, norB, norC, sdrM, and multi-drug and toxin 
compound extrusion (MATE) family MDR pump, 
mepA, are located on the chromosome4-8. One of the 
major concerns is the presence of efflux genes leading 
to resistance to broad spectrum of biocides and 
fluoroquinolenes9. Ethidium bromide is often used to 
study the presence of the efflux pump and the 
mechanism of antibiotic resistance in bacteria10,11. 
Apart from its role in antibiotic resistance, efflux 
pumps had been reported playing a role in biofilm 
formation12, pathogenicity, and virulence13.  
 
Biofilm, an aggregate of microbial cells embedded 
in the extracellular matrix, is one of the critical factors 
developing antimicrobial resistance and tolerance14-16. 
Several environmental factors, such as nutritional and 
metabolic cues, host-derived signals, quorum signal, 
and sub-inhibitory concentration of antimicrobials, 
contribute to biofilm formation17. The efflux pumps 
expression level, efflux harmful molecules and efflux 
pump substrates may influence biofilm formation18. 
Efflux pump inhibitors (EPI) alone or in combinations 
have been shown to either reduce or altogether abolish 
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the biofilm formation and antibiotic resistance19,20. The 
EPIs have been shown to affect the expression of efflux 
pumps by inhibiting the drug transport, interfering with 
the energy metabolism to transport the drug or by 
blocking the efflux channel21. Reserpine, LY35979, 
phenothiazine-metal complexes, and verapamil have 
side effects but reported to inhibit the bacterial efflux 
system and restoring antibiotic sensitivity22,23. In this 
regard, certain medicinal herbs are being screened, 
which have shown to inhibit the efflux pump of many 
microorganisms24. It was reported that methicillin 
sensitive Staphylococcus aureus (MRSA) and 
methicillin sensitive S. aureus (MSSA) strains does  
not contain the same set of efflux genes when isolated 
from the same hospital setting9. There are not many 
studies showing the relationship between efflux pumps 
and biofilm formation in both MRSA and MSSA 
strains. 
 
In this study, we determined the inhibitory  
and sub-inhibitory concentrations of ciprofloxacin, 
norfloxacin, chloramphenicol, penicillin, erythromycin, 
moxi-floxacin, and ethidium bromide in MRSA and 
MSSA strains. We tested the effect of inhibitors and 
phytochemicals on efflux pump, and biofilm 
formation, and correlated the results with the 
expression of genes encoding for multidrug resistant 
efflux pumps in MRSA and MSSA strains. 
 
Materials and Methods 
 
Bacterial isolates 
A total of five strains, two each of MRSA and 
MSSA and ATCC 25293, characterized previously, 
were included in the study.  
 
PCR assays 
PCR determined the presence of efflux pump genes, 
namely norB, norC, mdeA, lmrS, mepA and abcA25,26. 
The amplified products were separated on 1% agarose 
gel, stained with ethidium bromide, and visualized in 
Fluoro-S-MultiImager (Bio-Rad, USA). The details of 
the primers are given in Table 1. 
 
Sequencing of quinolone resistance determining region 
The PCR determines the presence of gyrA, gyrB, 
grlA and grlB genes in quinolone resistant determining 
region (QRDR) as described earlier4,27. The amplified 
products were purified (ExoSAP; Affymetrix, 
Cleveland, USA), and both strands were sequenced 
using an ABI sequencer model 3500 (Life Technologies, 
Marsiling, Singapore) at the sequencing facility of the 
Institute of Life Sciences, Bhubaneswar, India. 
Semi-quantitative estimation of biofilm formation 
The biofilm assay was performed by employing the 
method of Fredheim et al.28 with some modifications. 
Briefly, bacterial cultures were diluted to the 
absorbance of OD 0.05 at 595 nm. One mL of diluted 
culture was then added to 24-well polystyrene plates 
(COSTAR; Sigma) and allowed to grow for 24 h at 
37C under static condition. The planktonic cells were 
removed by pipette, and pallets washed once with 1X 
PBS and stained with 125 µL of 0.1% crystal violet for 
30 min at room temperature (25C). The bound dye 
was dissolved in 95% ethanol, and absorbance was 
recorded at 570nm (Nivo Multimode reader). The 
assay was performed in a single run of three wells in 
biological triplicates. Strains were considered biofilm 
positive if they had an OD of≥0.3. 
 
The detachment assay was performed to determine 
the components of biofilm matrix by the method of 
Fredheim et al.28 using reagent and enzymes (i) 40 mM 
sodium periodate (NaIO4: Sigma; S1878), (ii) 0.5 mg/mL 
proteinase K (Sigma; P2308), and (iii) 0.5 mg/mL 
DNase I (Sigma; DN25). Diluted bacterial strains were 
seeded to 24-well polystyrene plates (COSTAR; Sigma) 
and were allowed to grow for 24 h at 37oC under static 
Table 1 — List of primers of efflux pump genes used in this study 
Genes Primer sequence (5'-3') 
Amplicon 
size (bp) Ref. 
NorA-F TTCACCAAGCCATCAAAAAG 620 
 
29 
 NorA-R CTTGCCTTTCTCCAGCAATA 
NorB-F AGCGCGTTGTCTATCTTTCC 213 
 
22 
 NorB-R GCAGGTGGTCTTGCTGATAA 
NorC-F AATGGGTTCTAAGCGACCAA 216 
 
22 
 NorC-R ATACCTGAAGCAACGCCAAC 
MepA-F ATGTTGCTGCTGCTCTGTTC 718 
 
22 
 MepA-R TCAACTGTCAAACGATCACG 
MepA (RT)-F TGCTGCTGCTCTGTTCTTTA 198 
 
22 
 MepA (RT)-R GCGAAGTTTCCATAATGTGC 
MdeA-F AACGCGATACCAACCATTC 677 
 
22 







 MdeA (RT)-R 
AATTAATGCAGCTGTTCCGA
TAGA 
16S-F ACTCCTACGGGAGGCAGCAGT 180 
 
28 
 16S-R TATTACCGCGGCTGCTGGC 
AbcA-F CAGTGGTTTGTTAGGGCGTGTC 175 
 
This 










lmrS (RT)-F GCAATGGGACTAGCAGGTTTA 150 
 
This 
study lmrS (RT)-R AAATGGTACTCGCCAACTCG 




condition. Then the above reagents were added to 
individual wells after 24 h. After incubation, the biofilm 
was disrupted by mixing, and remaining adhered cells 
were quantified by crystal violet staining by the 
method described above. The percent detachment was 
calculated from the average difference between the 
treated wells and the control wells and divided the 
results into three categories: (i) no detachment (<10%), 
(ii) intermediate detachment (10–50%), and (iii) strong 
detachment (>50%). 
 
Minimum inhibitory concentration of EPI 
The minimum inhibitory concentration (MIC) of all 
strains of S. aureus was tested by broth micro-dilution 
assay following the method described in Clinical and 
Laboratory Standards Institute (CLSI) manual29. The 
antibiotics that showed substrate specificity for the 
efflux pump in S. aureus were tested. These antibiotics 
were ciprofloxacin, norfloxacin, ethidium bromide, 
oxacillin, penicillin, chloramphenicol, erythromycin, 
and moxifloxacin. S. aureus strain ATCC 25923 was 
used as a control. 
 
Ethidium bromide accumulation assay  
The four strains of S. aureus and control strain 
ATCC 25923 were subjected to accumulation assay. 
Briefly, bacterial cultures were grown in 2 mL tryptic 
soy broth (TSB) medium at 37C until they reach an 
OD600 of 0.6. The culture was centrifuged at 13000 ×g 
for 3 min, and the pellet was washed with 1X 
phosphate buffered saline (PBS). After adjusting the 
culture OD to 0.3 with 1X PBS, 0.4% glucose was 
added to the microtube containing 1.0 mL of the 
bacterial suspension. Then ethidium bromide (EtBr) 
ranging from 0.25-5 mg/L was added into a 96-well 
plate (Corning, Costar) containing 100 μL bacterial 
suspension of control strain ATCC 25923. The 
fluorescence was measured in the Nivo Multimode 
reader using 530 nm band pass and the 585 nm high 
pass filters as the excitation and detection wavelength, 
respectively. The fluorescence was captured after 
every 60 s for 60 min. MIC and half MIC of efflux 
inhibitors were determined. The concentration was as 
follows: 64 mg/L for thioridazine (TZ), 64 mg/mL for 
chlorpromazine (CPZ), 128 mg/L for reserpine, 0.5 mg/L 
for carbonyl cyanide 3-chloro-phenylhydrazone (CCCP), 
75 mg/L for naringenin, 75 mg/L for quercetin and  
50 mg/L for pyrogallol, respectively. The strains were 
suspended in 1X PBS at OD 600 of 0.3. The 
fluorescence of EtBr was measured at 530/585 nm after 
every 60 s for 60 min in the Nivo Multimode reader. 
 
Efflux pump activity of ethidium bromide 
All the four S. aureus strains were grown in 2 mL 
of TSB until they reached a mid-log phase. The cells 
were centrifuged at 13000 ×g for 3 min, then pellet 
washed with PBS and suspended the same at OD600 of 
0.3. Ethidium bromide was added to obtain a final 
concentration of 0.5 mg/L and measured the fluorescence 
in Nivo Multimode reader at 25C for 60 min. The TZ 
and CPZ that showed an effect on the accumulation of 
EtBr was determined under condition which optimize 
efflux in the presence of glucose and incubation at 25C. 
 
Effect of efflux pump inhibitors on biofilm formation 
The inhibition of biofilm produced by four strains of S. 
aureus, two each of MRSA and MSSA, was determined 
by adding the efflux pump inhibitors (EPIs) to the wells 
containing bacteria at 0 h and after 24 h. The wells were 
allowed to incubate for 24 h at 37C under static 
conditions. The plates were washed once with 1X PBS 
and then stained with 125 µL of 0.1% crystal violet for  
30 min at room temperature. The bound dye was 
dissolved in 95% ethanol, and absorbance was recorded 
at 570 nm (Nivo Multimode reader).  
 
qPCR and expression of efflux pump genes  
The expression of the efflux pump genes norB, norC, 
mepA, mdeA, abcA and lmrS was determined by the 
method described earlier24,30. The inhibitor's effect on 
the biofilm was evaluated after treatment with TZ, CPZ 
and naringenin at their ½ MIC and MIC at 0 h and after 
24 h. Briefly, the aliquots of 6 h grown culture in TSB 
diluted to an absorbance of 0.05 OD at 595 nm were 
seeded into 12-well plate (Corning). Then the inhibitors 
were added at 0h and after 24h and incubated at 37C 
for 24 h. Cells without inhibitor was used as a negative 
control. The non-adherent cells were discarded, and the 
adherent cells scraped by ice-chilled resuspension buffer 
(50 mM Tris-HCl, 10 mM EDTA, 500 mM NaCl, pH 
8.0). The biofilm cells were centrifuged for 5 min at 
18000 ×g at 4C. RNA was isolated by Trizol reagent 
(In vitro) using RNAiso Plus (Takara Clontech) 
according to the manufacturer’s instructions, and 
synthesized cDNA using Reverse transcriptase Core kit 
(Eurogentec). Quantitative RT-PCR (qRT-PCR) was 
performed using the SYBR Green Mastermix 
(Promega) in the Applied Biosystem 3000™ thermal 
cycler. The relative gene expression was determined 
using the comparative threshold cycle (CT) method and 
compare the expression of genes in the presence or 
absence of EPI. The 16S rRNA gene was used as a 
control31. 







All the strains of S. aureus, except MSSA strain 
N297214 negative for norA gene, were positive by PCR 
for norA, norB, norC, mdeA and abcA genes (Table 2). 
However, both MSSA strains were positive for lmrS and 
mepA genes. S. aureus strain ATCC 25923 was negative 
for the lmrS gene (Table 2).  
 
Mutations in QRDR of fluoroquinolones 
MRSA and MSSA isolates showing mutations in 
DNA gyrase genes, gyrA, gyrBand topoisomerase IV 
genes, grlA and grlBof QRDR are shown in Table 3. All 
the four strains were resistant to gatifloxacin, ofloxacin, 
ciprofloxacin and moxifloxacin, respectively. MRSA 
and MSSA strains showed mutation at position 
Val378Phe in the gyrB gene. However, MRSA strain 
N307002 and MSSA strain 2493 showed additional 
mutation at position Phe493Leu in the gyrB gene. Strain 
1079 carried mutation at Ser85Pro in the gyrA gene, 
Asp424Glu and Pro453Ser in grlB gene, but no 
variation in the grlA gene (Table 3). MSSA strain 
N297214 showed mutation at Ser84Ala in gyrA, 
Ile45Met, Phe80Tyr in grlA, and Gln385His, Glu386Pro 
in grlB, respectively. However, MSSA 2493 had no 
variation at gyrA and grlA but carried mutation at 
Asp509Gly in the grlBgene (Table 3). No mutation was 
found in the gyrA, gyrB and grlA genes of ATCC 25923. 
 
Biofilm formation and detachment assay 
All the four strains, two each of MRSA and MSSA, 
formed biofilm on polystyrene microtiter plates. Both 
MRSA strains formed healthy biofilm, but MSSA 
N297214 formed moderate to weak, and MSSA2493 
formed moderate biofilm. Strain ATCC 25923 formed 
a moderate to weak biofilm. Results of detachment 
assay performed with NaIO4, proteinase K and  
DNase I on MRSA and MSSA is shown in  
Fig. 1A. We found that all strains showed strong 
detachment after treatment with proteinase K, 
moderate detachment with DNase I, and low level 
detachment with NaIO4, respectively. The control 
strain S. aureus ATCC 25923 displayed strong 
detachment upon proteinase K treatment. Therefore, 
these strains had protein as their principal component 
in the biofilm matrix and were used for further study  
(Fig. 1B). 
Table 3 — Fluoroquinolone susceptibility and mutations found in QRDR genes in MRSA and MSSA strains 
 
Isolate No. 
Mutation(s) in QRDR genes encoding for MIC (mg/L) for antibiotics 









MRSA N307002 - Val378Phe, Phe493Leu Ser81Pro Asp424Glu 8 (R)  8 (R)  >64 (R) >64 (R) 







Gln385His, Gln386Pro >64 (R) >64 (R) >64 (R) >64 (R) 
MSSA 2493 - Val378Phe, Phe493Leu - Asp509Gly 8 (R)  8 (R)  >64 (R) 8 (R)  
ATCC 25923 - - - - 1 (S) 2 (S) 1 (S) <1 (S) 
Table 2 — Presence or absence of efflux pump genes in  
MRSA and MSSA strains 
S. aureus  
strains 
Presence of efflux pump genes encoding for 
norA norB norC mdeA lmrS mepA AbcA 
MRSA N307002 + + + + - - + 
MRSA 1079 + + + + - + + 
MSSA N297214 - + + + + + + 
MSSA 2493 + + + + + + + 
ATCC 25923 + + + + - + + 
 
 
Fig. 1 — (A) Quantification of biofilm formed by S. aureus strains 
in 24 h by crystal violet assay; and (B) Percent detachment of 
preformed biofilms obtained with MRSA and MSSA after 
treatment with NaIO4, proteinase K and DNase I. 




Effect of EPI on MIC 
MIC wasdetermined for antibiotics among MRSA 
and MSSA strains that ranged between <1 and >512 
μg/mL. TZ, CPZ, CCCP, reserpine, naringenin, 
quercetin and pyrogallol showed a reduction in MIC of 
antibiotics in S. aureus. TZ and CPZ showed a 
significant decrease in the MIC of antibiotics. 
However, CCCP, naringenin, quercetin and pyrogallol 
showed less effect on MIC. Reserpine had no or less 
inhibitory effect on MIC (Table 4). 
 
Accumulation of ethidium bromide 
The EtBr accumulation assay showed that the 
concentration of EtBr required for detection varied 
from strain to strain. One strain of MRSA and both of 
MSSA needed 0.5 mg/L EtBr, but MRSA strain 
N307002 showed accumulation atone mg/L of 
EtBr(Fig. 2). S. aureus ATCC 25923 showed an 
accumulation of EtBr at 0.25mg/L. CPZ showed 
inhibition of accumulation of EtBr in all strains. 
 
Moreover, TZ and CPZ showed an accumulation of 
EtBr at almost the same level in MRSA. Reserpine 
showed virtually a similar level of accumulation as TZ 
in MSSA 2493. Naringenin was the most effective 
inhibitor compared to quercetin and pyrogallol in all 
strains (Fig. 3). The most effective inhibitor for ATCC 
25923 was CPZ and TZ, followed by reserpine and 
naringenin.  
 
Intrinsic efflux activity of the MRSA and MSSA 
The conditions established by accumulation assays 
were used to load cells with EtBr and perform efflux 
assays by real-time fluorimeter. CPZ displayed unusual 
efflux pump activity compared to TZ. MRSA showed 
50%  efflux  activity,  while  MSSA  showed  60-70%  
Table 4 —MICs of antibiotics obtained before and after treatment with efflux pump inhibitors among MRSA and MSSAs strains 
Antibiotics  
and EPIs 
MIC of antibiotics after treatment of EPIs and 
shown by S. aureus isolates 
Antibiotics  
and EPIs 
MIC of antibiotics after treatment of EPIs and 























Ethidium bromide 32 64 64 32 8 Erythromycin >512 >512 1 >512 2 
TZ 4 2 2 <1 4 TZ 32 <1 <1 <1 <1 
CPZ <1 <1 4 4 2 CPZ 32 >512 <1 <1 2 
Res 4 32 64 32 32 Res >512 >512 2 >512 2 
CCCP 8 8 8 4 8 CCCP 64 >512 <1 <1 <1 
Naringenin 32 64 64 32 32 Naringenin >512 >512 16 256 256 
Quercetin 32 32 32 32 32 Quercetin >512 >512 16 32 32 
Pyrogallol 32 64 64 64 64 Pyrogallol >512 >512 32 >512 >512 
Ciprofloxacin 128 128 8 8 <1 Oxacillin 512 128 <1 <1 1 
TZ <1 <1 <1 <1 <1 TZ 8 4 <1 <1 <1 
CPZ <1 <1 <1 <1 <1 CPZ 128 <1 <1 <1 <1 
Res 64 128 <1 8 2 Res 512 >512 <1 128 1 
CCCP 16 16 8 16 <1 CCCP 256 >512 2 <1 1 
Naringenin 128 256 128 64 64 Naringenin >512 >512 >512 >512 >512 
Quercetin 256 256 64 64 64 Quercetin >512 >512 >512 >512 >512 
Pyrogallol 256 256 64 64 64 Pyrogallol >512 >512 >512 >512 >512 
Norfloxacin 512 512 16 32 <1 Penicillin 512 32 128 512 128 
TZ <1 128 8 8 <1 TZ 512 512 512 512 512 
CPZ 2 <1 <1 <1 <1 CPZ 512 512 512 512 512 
Res 256 256 8 16 64 Res >512 >512 >512 >512 >512 
CCCP 256 256 8 2 32 CCCP 512 512 512 >512 >512 
Naringenin 16 16 8 8 8 Naringenin >512 >512 >512 >512 >512 
Quercetin 16 8 8 8 2 Quercetin >512 >512 >512 >512 >512 
Pyrogallol 16 16 8 8 8 Pyrogallol >512 >512 >512 >512 >512 
Moxifloxacin 8 16 >64 8 1 Chloramphenicol 32 32 32 32 16 
TZ <0.125 <0.125 <0.125 <0.125 <0.125 TZ 16 16 16 16 16 
CPZ 8 <0.125 <0.125 <0.125 <0.125 CPZ 16 16 8 16 8 
Res 8 16 2 8 4 Res 16 16 32 16 8 
CCCP <1 <1 <1 <1 <1 CCCP 16 8 16 8 2 
Naringenin 0.25 16 2 8 8 Naringenin 128 128 64 128 128 
Quercetin 8 16 8 16 16 Quercetin 128 256 128 128 128 
Pyrogallol 16 8 8 8 8 Pyrogallol 128 128 64 8 8 
[TZ, Thioridazine; CPZ, Chlorpromazine; Res, Reserpine; CCCP, Carbonyl cyanide 3-chlorophenylhydrazone] 




efflux activity in the presence of CPZ (Fig. 4A). When 
TZ was used, efflux activity was 35-40% in MRSA and 
40-50% efflux activity in MSSA (Fig. 4B). S. aureus 
ATCC 25923 showed 50% efflux activity in the 
presence of CPZ and 30% efflux activity with TZ. 
When EtBr efflux was assessed in the presence of 
reserpine and naringenin, there was no basal level of 
efflux activity (data not shown).  
 
Effect of inhibitors on biofilm formation 
TZ, CPZ, reserpine, and naringenin efficacy at sub-
inhibitory concentrations were assessed on biofilm 
formation. At 0 h, MRSA N307002 with TZ and CPZ 
didn’t show any effect on biofilm formation while 
reserpine and naringenin were able to reduce the 
biofilm by 50-60%. Although TZ did not affect MRSA 
1079, however, CPZ and reserpine and naringenin 
reduced biofilm by 20 - 80% (Fig. 5). On the other 
hand, there was no effect of inhibitors on biofilm 
formation in MSSA N297214. However, naringenin 
showed 40% reduction in biofilm formation. Similarly, 
CPZ had no impact on MSSA 2493. However, TZ and 
reserpine showed 30% reduction in biofilm while 
naringenin had 60% reduction in biofilm. No effect of 
the inhibitors was observed in decreasing the biofilm 
formation of control strain ATCC 25923 (Fig. 5).  
After 24 h, MRSA strains showed no significant 
reduction in biofilm formation; however, MSSA 




Fig. 2 — Real-time assessment of ethidium 
bromide accumulation in MRSA N307002 & 
MRSA 1079; MSSA N297214 & MSSA 2493; and 
reference strain ATCC 25923 




with naringenin, but no effect was observed in MSSA 
2493 (Fig. 5). The biofilm formation in control strain 
ATCC 25923 was reduced by 10% with TZ and 20% 
with CPZ but no effect was observed with other 
inhibitors (Fig. 5). 
 
TZ, CPZ, reserpine and naringenin efficacy was 
further assessed at inhibitory concentrationon biofilm 
formation. At 0 h, MRSA N307002 showed a 
significant reduction in biofilm formation with all 
inhibitors; however, MRSA 1079 and MSSA ATCC 
25923, except reserpine, also showed a decrease in 
biofilm formation (Fig. 5).  
 
MRSA strains did not affect biofilm formation 
when TZ and reserpine were added after 24 h; however, 
MRSA N307002 showed a reduction in biofilm 
formation with CPZ and naringenin. On the other hand, 
MRSA 1079 showed a decrease in biofilm formation 
with CPZ, but no effect was observed with naringenin 
(Fig. 5). MSSA N297214 showed a reduction inbiofilm 
with all inhibitors; however, MSSA 2493 showed a 
decrease with TZ but not with other inhibitors. ATCC 
25923 had an inhibitory effect on biofilm formation 






Fig. 3 — Real-time assessment of EtBr 
accumulation in the presence of efflux inhibitors. 
[The efflux pump inhibitor were tested at a sub-
inhibitory concentration. Thioridazine 64 mg/L, 
chlorpromazine 64 mg/mL, reserpine 128 mg/L, 
CCCP 0.5 mg/L, naringenin 75 mg/L, quercetin 75 
mg/L and pyrogallol 50 mg/L] 






Fig. 4 — Ethidium bromide efflux assay was done in the presence/absence of 0.4% glucose, with or without the efflux inhibitor at a sub-




Fig. 5 — Effects of thioridazine, chlorpromazine, reserpine and naringenin at half MIC and MIC on biofilm formation of MRSA and 
MSSA strains. (A) Inhibitors were added initially (0 h) at half MIC and MIC, and the biofilm was determined after 24 h; and (B) Inhibitors 
were added after 24 h of biofilm at half MIC and MIC, and the biofilm inhibition was determined after 48 h 
 




Efflux pump gene expression in biofilm 
The gene expression of norB, norC, mdeA, lmrS 
(MFS family), mepA (MATE family) and abcA (ABC 
family) in biofilm was determined in the presence of 
efflux inhibitors TZ, CPZ and naringenin at 0 h  
(Fig. 6A). TZ downregulated the norB, norC, mepA and 
abcA genes in MRSA; however, MSSA showed a 
reduction in the expression of norB, norC and abcA 
genes. The expression pattern of ATCC 25923 was 
similar to that of MRSA strains. CPZ upregulated the 
expression of the mdeA gene but downregulated other 
genes in MRSA isolates (Fig. 6A). Whereas norB, 
norC, lmrS and abcAgenes were downregulated by 
CPZ in MSSA N297214, MSSA 2493 showed 
downregulation of norC, lmrS and abcAgenes.  
S. aureus ATCC 25923 downregulation of norB, norC, 
mepA and abcA genes with chlorpromazine. On the 
other hand, naringenin showed reduced expression of 
the mepA gene in MSSA but downregulation of norB 
and lmrSgenes in MRSA and norB, lmrS and 
mepAgenes in ATCC 25923 (Fig. 6A). Thus, TZ, CPZ 
and naringenin affect the genes belonging to MFS, 
MATE and ABC family. 
 
When TZ added after 24 h in biofilm, MRSA 
N307002 showed downregulation of lmrS gene; 
however, MRSA 1079 showed downregulation of lmrS 
and abcA genes. On the other hand, MSSA N292714 
showed reduced expression of norB and mepA genes, 
but MSSA 2493 showed downregulation of norB, 
mdeA and lmrS genes (Fig. 6B). CPZ showed reduced 
expression of lmrS and mepA genes in MRSA but 
norB, norC and abcAgenes in MSSA N297214 and 
norB, norC, lmrS, mepA and abcA genes in MSSA 
2493. The downregulation of norB, norC, mepA was 
observed in ATCC 25923 (Fig. 6B). Naringenin, 
downregulated the expression of norB, norC, lmrS and 
mepA genes in MRSA N307002 but norB, norC, lmrS 
and abcA genes in MRSA 1079. In contrast, MSSA 
N297214 showed downregulation of norB, lmrS and 
mepA genes, but MSSA 2493 downregulated all genes 
except for the mdeA and lmrS genes. The expression of 
norB, norC and lmrS was affected by naringenin in  
S. aureus ATCC 25923 (Fig. 6B). Therefore, TZ, CPZ, 
and naringenin inhibited genes belonging to either MFS 




Several workers reported the occurrence of 
antibiotic resistance among S. aureusstrains, of which 
MRSA acquires additional antibiotic resistance 
genes32,33. This phenomenon is not only limited to 
planktonic bacteria but also extends to biofilm. MRSA 
 
 
Fig. 6 — Efflux pump gene expression determined 
by qPCR in the biofilm of MRSA and MSSA 
strains after exposure to thioridazine, 
chlorpromazine, and naringenin for (A) 24 h; and 
(B) 48 h 




showed the presence of efflux pump genes norA, norB, 
norC, mdeA, mepA and abcA gene, which is similar to 
those workers who also reported the existence of efflux 
pumps genes in MRSA34. Besides, MSSA strains is 
also shown to carry genes, namely norA, norB, norC, 
mdeA, lmrS, mepA and abcA which was not reported 
earlier among S. aureus strains. 
 
Several mutations have been reported in S. aureus 
showing resistance to fluoroquinolones. These 
mutations are mainly attributed by QRDRs of the DNA 
gyrase and the topoisomerase IV genes encoding for 
gyrA, gyrB, grlA and grlB3,35. MRSA and MSSA 
strains were resistant to gatifloxacin, moxifloxacin, 
ciprofloxacin and ofloxacin. They showed MIC in 
range of from 8 to >64 mg/L. For the first time, we 
found additional mutations in the QRDRs of MRSA 
and MSSA strains. These mutations in gyrA, gyrB, grlA 
and grlB among S. aureus lead to a higher level of MIC 
for fluoroquinolones. These observations, thus suggest 
that mutations are continuously occurring in S. aureus 
strains, which should be monitored in real-time to track 
the changes in antibiotic resistance. 
 
Staphylococcus aureus strains were resistant to 
fluoroquinolones and showed high MIC values. We 
found the role of efflux inhibitors TZ, CPZ and CCCP 
in reducing the MIC for fluoroquinolones, ethidium 
bromide, and other antibiotics indicating their role as 
efflux pump inhibitors among S. aureus strains. Our 
results corroborate with the findings of other workers 
who have reported a reduction in MIC of antibiotics 
after exposure to TZ and CPZ36. Similarly, reserpine 
was shown to reduce the MIC of antibiotics among  
S. aureus10. Phenothiazine was shown to alter the 
susceptibility of oxacillin in MSSA and MRSA 
strains35. Although this study showed the reduction of 
MIC for oxacillin in MRSA strains with TZ and CPZ 
but no effect was found with reserpine. 
 
In contrast, reserpine reduced the MIC of 
ciprofloxacin and moxifloxacin in MRSA and MSSA 
strains. This finding is similar to those who have shown 
a reduction in the MIC of norfloxacin and 
ciprofloxacin37. It shows that TZ, CPZ and resperine 
can be used effectively in reducing the MIC of 
antibiotics, thus facilitating the action of these drugs in 
the treatment of infection. 
 
Flavonoids, quercetin, naringenin and pyrogallol 
have antimicrobial activities38. In this study, we found 
naringenin at 75 mg/L (275.5µM) concentration 
showing a reduction in MIC of norfloxacin and 
moxifloxacin in MRSA and MSSA strains. This 
observation, thus indicates the role of this compound 
as an effective efflux pump inhibitor. Naringenin was 
found to be an effective efflux pump inhibitor after 
reserpine, as demonstrated by ethidium bromide 
accumulation assay. In the past, EtBr-reserpine 
combination has been used as a standard control to 
study the efflux activity in S. aureus39,40. Also, CCCP 
found to increase EtBr fluorescence41. In contrast, CPZ 
was found most effective inhibitor followed by TZ that 
leads to ethidium bromide accumulation. These 
findings thus suggests that flavonoid may be used as 
effective efflux pump inhibitors. 
 
We evaluated the ability of TZ, CPZ and reserpine 
at two different time points of biofilm formation. At the 
initial time point and sub-inhibitory concentration, TZ 
did not affect, but CPZ had some effect on biofilm 
formation in MRSA. In contrast, TZ reduced biofilm 
formation in MSSA, but CPZ did not show any effect 
on biofilm formation. These observations thus indicate 
that TZ and CPZ at their MIC, showed significant 
effect on biofilm formation among MRSA and MSSA 
strains, suggesting their role in biofilm formation. 
Earlier workers have also demonstrated the role of 
CCCP and CPZ in biofilm formation in S. aureus42. 
Naringenin was reported to be an effective inhibitor in 
the biofilm, suggesting a self defense function for this 
compound in its natural niche. In this study, naringenin 
showed a significant reduction in biofilm formation in 
MRSA and MSSA strains. However, in 24 h grown 
biofilm, CPZ and naringenin was found effective 
against MRSA but TZ was effective against MSSA. 
This observation thus suggests that TZ, CPZ and 
naringenin act differently among MRSA and MSSA 
strainsdepending on duration of growth of biofilm.  
 
Staphylococcus aureus has been reported to 
upregulate the expression of efflux pump genes during 
biofilm growth43. Several workers have identified the 
use of efflux pump inhibitors as antibiofilm agents17. 
In this study, we found a differential gene expression 
pattern in the biofilm after treatment with inhibitors. 
CPZ and TZ had shown reduced expression of norB, 
norC, mepA, abcA and to a certain extent lmrS genes in 
the biofilm formed by MRSA but norB, norC and abcA 
genes in MSSA thereby reducing the biofilm 
formation. This finding thus indicates the role of these 
inhibitors in biofilm formation among MRSA and 
MSSA strains. Similar to TZ and CPZ, naringenin also 
showed downregulation of MFS, MATE, and ABC 
genes leading to the reduction of biofilm. This finding 




thus suggests their role in the inhibition of biofilm 
formation. 
The methodologies applied in this study showed that 
efflux activity is an essential component of the 
resistance to fluoroquinolones and other antibiotics 
that are substrates of different efflux pumps in MRSA 
and MSSA strains. TZ, CPZ, reserpine and 
naringeninwere found to inhibit the efflux pump 
system that may be used as an antibiofilm agent. There 
is a need for further study to combine broad spectrum 
efflux pump inhibitors with antibiotics that could help 
in the treatment of S. aureus infections. 
 
Conclusion 
The reduction in MIC of antibiotics in the presence 
of efflux inhibitors showed that efflux activity is  
an essential component of the resistance to fluoro-
quinolones and other antibiotics that are substrates of 
different efflux pumps in MRSA and MSSA strains. 
The expression study on efflux pump genes indicated 
that TZ, CPZ, reserpine and naringenin were found to 
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